Taiwan's Cell Therapy: 20 Years of Progress - Reviewing Current Clinical Trials
The much-debated Regenerative Medicine Act has been the subject of ongoing discussions for many years. Though it has consolidated from three draft guidances into two, a definitive solution remains elusive. When will the first step be taken?
Currently, nearly a hundred companies in Taiwan have registered for cell therapy, with 31 biotech companies actively involved in cell therapy research, encompassing 65 clinical trial programs. What is the status of these clinical trials?
Compared to traditional pharmaceuticals, what are the additional challenges faced in clinical trials for cell therapy? In this issue, we have interviewed four clinical trial doctors and three CRO companies in Taiwan to provide you with insights from frontline personnel involved in clinical trials.
Visit #GlobalBio issue 109 for more information about Cell Therapy in Taiwan:
https://bit.ly/buyv109
#celltherapy #ClinicalTrials #RegenerativeMedicine
Taiwan's Cell Therapy: 20 Years of Progress - Reviewing Current Clinical Trials
撰文GlobalBio & Investment
日期2023-12-01
![](/upload/article/periodical/v109/v109封面故事.jpg)
Taiwan's Cell Therapy: 20 Years of Progress - Reviewing Current Clinical Trials